MedPath

Effect of a Menohelp Barij® capsule on early symptoms of menopause

Phase 3
Conditions
The early menopausal symptoms.
Menopausal and other perimenopausal disorders
Registration Number
IRCT20100414003706N35
Lead Sponsor
Barij Essence Pharmaceutical Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
100
Inclusion Criteria

Aged 50-59 years
12-72 months after last menstrual period
Natural menopause
Having at least 3 hot flashes daily during one week follow-up
Living with husband
BMI 18 to 30 kg/m2
Having a least 6 years Education

Exclusion Criteria

Contraindications for hormone therapy, including history of breast cancer, endometrial hyperplasia, or any estrogen-related cancers in the woman or her first-degree family
Use of hormone therapy during past 3 months
Allergy to estrogen or medicinal herbs
Any history of cervical cancer, liver diseases, kidney diseases, gastrointestinal diseases, coagulation diseases, depression or hyperthyroidism.
Surgery during the past 3 months
Chronic diseases requiring treatment including severe hypertension (160/110) and known diabetes, or malabsorption syndrome
Myocardial or cerebral infarction over the past 3 months or History of complicated myocardial or cerebral infarction
History of venous thrombosis
history of known fibromyoma
Heavy smoker (more than 15 cigarettes/day)
Regular consumption of alcoholic beverages and alcohol dependence

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall score and sub-scales (vasomotor, physical, psychological, and sexual symptoms) of early menopausal symptoms. Timepoint: Before intervention and 4 and 12 weeks after intervention. Method of measurement: Green climacteric scale.;Number of daily hot flashes. Timepoint: before intervention and 4 and 12 weeks after intervention. Method of measurement: daily registration form.;Severity of hot flashes. Timepoint: before intervention and 4 and 12 weeks after intervention. Method of measurement: daily registration form.
Secondary Outcome Measures
NameTimeMethod
Total and subscales scores of quality of life. Timepoint: before intervention and 12 weeks after intervention. Method of measurement: The Menopause-Specific Quality of Life (MENQOL).;Total improvement status for early symptoms of menopause. Timepoint: 4 and 12 weeks after intervention. Method of measurement: one question with three Likert options.;Quality of sleep score. Timepoint: 4 weeks after intervention. Method of measurement: The Pittsburgh Sleep Quality Index (PSQI).
© Copyright 2025. All Rights Reserved by MedPath